Literature DB >> 19229612

Is furazolidone therapy for Helicobacter pylori effective and safe?

Vincenzo De Francesco, Enzo Ierardi, Cesare Hassan, Angelo Zullo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19229612     DOI： 10.1007/s10620-009-0748-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  13 in total

Review 1.  Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure.

Authors:  J P Gisbert; F Morena
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

2.  Naphthofuroquinone derivatives: inhibition of receptor tyrosine kinases.

Authors:  Kee-In Lee; Youmie Park; Su-Jin Park; Jung-Hwan Hwang; Sung-Jin Lee; Gun-Do Kim; Woo-Kyu Park; Sunghou Lee; Daeyoung Jeong; Jae-Yang Kong; Hee-Kyoung Kang; Heeyeong Cho
Journal:  Bioorg Med Chem Lett       Date:  2006-02       Impact factor: 2.823

Review 3.  Genotoxicity and carcinogenicity of metronidazole.

Authors:  L Dobiás; M Cerná; P Rössner; R Srám
Journal:  Mutat Res       Date:  1994-06       Impact factor: 2.433

4.  Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats.

Authors:  M Tatsuta; H Iishi; M Baba; H Taniguchi
Journal:  Int J Cancer       Date:  1991-06-19       Impact factor: 7.396

5.  Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease.

Authors:  Guilherme-Eduardo-Goncalves Felga; Fernando-Marcuz Silva; Ricardo-Correa Barbuti; Tomas Navarro-Rodriguez; Schlioma Zaterka; Jaime-Natan Eisig
Journal:  World J Gastroenterol       Date:  2008-10-28       Impact factor: 5.742

6.  Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy.

Authors:  Zaigham Abbas; Javed Yakoob; Shahab Abid; Wasim Jafri; Muhammad Islam; Zahid Azam; Imran Hilal
Journal:  Dig Dis Sci       Date:  2008-12-05       Impact factor: 3.199

7.  Efficacy of a new therapeutic regimen versus two routinely prescribed treatments for eradication of Helicobacter pylori: a randomized, double-blind study of doxycycline, co-amoxiclav, and omeprazole in Iranian patients.

Authors:  Seyed Alireza Taghavi; Ali Jafari; Ahad Eshraghian
Journal:  Dig Dis Sci       Date:  2008-07-02       Impact factor: 3.199

8.  Potential role of cysteine and methionine in the protection against hormonal imbalance and mutagenicity induced by furazolidone in female rats.

Authors:  Hanaa H Ahmed; Sekena H Abd El-Aziem; Mosaad A Abdel-Wahhab
Journal:  Toxicology       Date:  2007-09-22       Impact factor: 4.221

Review 9.  Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis.

Authors:  Alexander C Ford; Peter Malfertheiner; Monique Giguere; Jose Santana; Mostafizur Khan; Paul Moayyedi
Journal:  World J Gastroenterol       Date:  2008-12-28       Impact factor: 5.742

Review 10.  Nitrofuran-based regimens for the eradication of Helicobacter pylori infection.

Authors:  György M Buzás; Jolán Józan
Journal:  J Gastroenterol Hepatol       Date:  2007-10       Impact factor: 4.029
View more
  3 in total

Review 1.  Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis.

Authors:  Angelo Zullo; Enzo Ierardi; Cesare Hassan; Vincenzo De Francesco
Journal:  Saudi J Gastroenterol       Date:  2012 Jan-Feb       Impact factor: 2.485

2.  Eradication Treatment of Helicobacter pylori Infection: Its Importance and Possible Relationship in Preventing the Development of Gastric Cancer.

Authors:  Bruna Maria Roesler; Sandra Cecília Botelho Costa; José Murilo Robilotta Zeitune
Journal:  ISRN Gastroenterol       Date:  2012-06-13

3.  Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance.

Authors:  Muhammad Miftahussurur; Langgeng Agung Waskito; Ari Fahrial Syam; Iswan Abbas Nusi; Gontar Siregar; Marselino Richardo; Achmad Fuad Bakry; Yudith Annisa Ayu Rezkitha; I Dewa Nyoman Wibawa; Yoshio Yamaoka
Journal:  Infect Drug Resist       Date:  2019-01-31       Impact factor: 4.003
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.